Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Eytan M. Stein, Jörg Chromik, Cecilia Carpio, Rogier Mous, Jean-Jacques Kiladjian, Gheath Alatrash, Antonio Curti, Charles Craddock, Christoph Schmid, Robert Zeiser, Lamis K. Eldjerou, Hans-Jochen Jochen Weber, Claire Fabre, Jeffrey Scott, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2021-149751

Published: 2021

Journal Articles

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Andrew H. Wei, Massimo Breccia, Melissa Ooi, Maria Teresa Cedena Romero, Fabio Ciceri, Harry P. Erba, Anil Gaur, Romain Sechaud, Ensar Halilovic, Brigitte Kuenzle, Claire Fabre, Kimmo Porkka

Blood (2021) 138 (Supplement 1): 1283.

https://doi.org/10.1182/blood-2021-144650

Published: 2021

Journal Articles

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blood (2012) 119 (24): 5772–5781.

https://doi.org/10.1182/blood-2011-07-366633

Published: 2012

Includes: Supplemental data

Journal Articles

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

Gullu Gorgun, PhD, Teru Hideshima, MD, PhD, Noopur S. Raje, MD, Naoya Mimura, MD, PhD, James E. Bradner, MD, Diana Cirstea, MD, Loredana Santo, MD, Yu-Tzu Tai, PhD, Michael Sellitto, Yiguo Hu, PhD, Claire Fabre, MD, PhD, Hiroto Ohguchi, MD, PhD, Jiro Minami, MD, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 128.

https://doi.org/10.1182/blood.V118.21.128.128

Published: 2011

Journal Articles

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Blood (2011) 118 (21): 133.

https://doi.org/10.1182/blood.V118.21.133.133

Published: 2011

Journal Articles

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

Claire Fabre, MD, PhD, Naoya Mimura, MD, PhD, Kathryn Bobb, MS, Gullu Gorgun, PhD, Diana D. Cirstea, MD, Yiguo Hu, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Jie Zhang, PhD, Jeffrey Meshulam, BS, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 2902.

https://doi.org/10.1182/blood.V118.21.2902.2902

Published: 2011

Journal Articles

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

Diana Cirstea, MD, Teru Hideshima, MD, PhD, Loredana Santo, MD, Homare Eda, MD, PhD, Miriam Canavese, PhD, Tyler A. Scullen, BA, Anuj K. Mahindra, MD, Gullu Gorgun, PhD, Yiguo Hu, MD, PhD, Naoya Mimura, MD, PhD, Claire Fabre, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Kenneth C. Anderson, MD, Sylvie M Guichard, PharmD, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2916.

https://doi.org/10.1182/blood.V118.21.2916.2916

Published: 2011

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma

Gullu Gorgun, PhD, Teru Hideshima, MD, PhD, Naoya Mimura, MD, PhD, Diana Cirstea, M.D., Loredana Santo, MD, Yiguo Hu, MD, PhD, Claire Fabre, MD, Noopur Raje, MD, Nikhil C. Munshi, MD, Paul G Richardson, MD, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 2996.

https://doi.org/10.1182/blood.V116.21.2996.2996

Published: 2010

Journal Articles

Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma

Naoya Mimura, Teru Hideshima, Gullu Gorgun, Diana Cirstea, Loredana Santo, Yiguo Hu, Claire Fabre, Martina Blumenthal, Victor Tam, Nathalie L. Kertesz, Qingping Zeng, John B. Patterson, Nikhil C. Munshi, Paul Richardson, Kenneth C. Anderson

Blood (2010) 116 (21): 4074.

https://doi.org/10.1182/blood.V116.21.4074.4074

Published: 2010

Journal Articles

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Güllü Görgün, Elisabetta Calabrese, Ender Soydan, Teru Hideshima, Giulia Perrone, Madhavi Bandi, Diana Cirstea, Loredana Santo, Yiguo Hu, Yu-Tzu Tai, Sabikun Nahar, Naoya Mimura, Claire Fabre, Noopur Raje, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson

Blood (2010) 116 (17): 3227–3237.

https://doi.org/10.1182/blood-2010-04-279893

Published: 2010

Includes: Supplemental data

Journal Articles

Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française de Greffe de Moelle Thérapie Cellulaire (SFGM-TC).

Claire Fabre, Serge Koscielny, Jean-Luc Harousseau, Mohamad Mohty, Didier Blaise, Noël Milpied, Bernard Rio, Mauricette Michallet, Thierry Facon, Jean-Paul Vernant, Agnès Buzyn, Gérard Socié, Jean-Yves Cahn, Natacha Maillard, Jacques-Olivier Bay, Jean-Henri Bourhis

Blood (2009) 114 (22): 1188.

https://doi.org/10.1182/blood.V114.22.1188.1188

Published: 2009

Journal Articles

Tandem Autologous/Allogeneic Stem Cell Transplantation for Multiple myeloma: Long-Term Outcome of a Retrospective Study

Claire Fabre, Jalil Bennani, Alain Brebion, Jean Mendiboure, Vincent Ribrag, Christophe Ferme, Nathalie Auger, Naziha Menasria, Annelise Bennaceur-Griscelli, Frédéric Troalen, Valérie Lapierre, Jean-Henri Bourhis

Blood (2008) 112 (11): 4389.

https://doi.org/10.1182/blood.V112.11.4389.4389

Published: 2008

Journal Articles

Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program

Blood (2008) 112 (11): 2682.

https://doi.org/10.1182/blood.V112.11.2682.2682

Published: 2008

Journal Articles

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, Génèviève Le Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Kroemer

Blood (2008) 111 (4): 2170–2180.

https://doi.org/10.1182/blood-2007-07-100362

Published: 2008

Includes: Supplemental data

Journal Articles

Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.

Blood (2007) 110 (11): 1849.

https://doi.org/10.1182/blood.V110.11.1849.1849

Published: 2007

Journal Articles

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 2438.

https://doi.org/10.1182/blood.V110.11.2438.2438

Published: 2007

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 399.

https://doi.org/10.1182/blood.V110.11.399.399

Published: 2007

Journal Articles

Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines.

Simone Boehrer, MD, PhD, Lionel Ades, MD, Claire Fabre, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2006) 108 (11): 2649.

https://doi.org/10.1182/blood.V108.11.2649.2649

Published: 2006

Journal Articles

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

Claire Fabre, MD, Fatsiha Chermat, Laurence Legros, MD, Sophie Park, MD, François Dreyfus, MD, Françoise Isnard, MD, Florence Nowak, MD, Anne Marfaing, MD, Stéphane de Botton, MD, Marie-Pierre Noel, MD, Christophe Fruchart, MD, Thomas Prebet, MD, Norbert Vey, MD, Caroline Dartigeas, MD, Pierre Fenaux, MD PhD

Blood (2006) 108 (11): 2664.

https://doi.org/10.1182/blood.V108.11.2664.2664

Published: 2006

NARROW

Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy

Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma

Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française de Greffe de Moelle Thérapie Cellulaire (SFGM-TC).

Tandem Autologous/Allogeneic Stem Cell Transplantation for Multiple myeloma: Long-Term Outcome of a Retrospective Study

Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program.

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines.

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only